Tirzepatide news

All news on Tirzepatide (also known as Mounjaro): plants, production capacities, investments and involved companies.

8 January 2026

Lilly's Taltz and Zepbound Show Superior Results in Psoriatic Arthritis and Obesity Trial

The trial showed Taltz and Zepbound together improved psoriatic arthritis and weight loss more than Taltz alone, with mild to moderate side effects.
1 December 2025

Lilly Reduces Price of Zepbound Vials

Zepbound single-dose vials are now cheaper, enhancing access for obesity patients. Starting doses cost $299/month, with higher doses at $399 and $449.
6 November 2025

Lilly and U.S. Government Expand Access to Obesity Drugs

Medicare beneficiaries to access obesity drugs at $50/month. LillyDirect offers self-pay options. FDA approval pending.
6 November 2025

Lilly Expands Leadership Team for Growth

Lilly appoints Carole Ho and Adrienne Brown to Executive Committee, expands roles for Daniel Skovronsky and Jacob Van Naarden to drive growth in neuroscience and immunology.
30 October 2025

Lilly Q3 2025 Financials: Revenue Up 54%, R&D Progress, Guidance Raised

Revenue growth driven by incretin demand. Advanced orforglipron trials, FDA approval for Inluriyo. Expanded manufacturing in Virginia, Texas, Puerto Rico.
31 August 2025

Novo Nordisk: Wegovy® Reduces Heart Attack, Stroke, Death Risk by 57% vs. Tirzepatide

Wegovy® shows 57% greater risk reduction in heart events vs. tirzepatide in obese patients with CVD. Benefits are specific to semaglutide, not general to GLP-1 or GIP/GLP-1 classes.

Who will be producing Tirzepatide in the future?

Find out with chemXplore Analytics